Ophthalmic pharmaceutical compositions and their uses
The ophthalmic pharmaceutical composition with latanoprostene bunod and semifluorinated alkanes addresses preservative-related issues and manufacturing challenges, providing effective intraocular pressure reduction with reduced side effects and improved stability.
Patent Information
- Application Number
- JP2026078000
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-06
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-19
AI Technical Summary
Existing ophthalmic drug formulations containing prostaglandin analogs face issues such as irritant reactions due to preservatives, limited drug delivery, visual interference, and complex manufacturing, especially for low-water-soluble drugs, which are not effectively addressed by current oily or aqueous solutions.
An ophthalmic pharmaceutical composition comprising latanoprostene bunod with an oil phase of semifluorinated alkanes and a liquid carrier, free of water and preservatives, formulated as a solution, emulsion, or suspension, with specific solubility and concentration ranges, enhancing stability and reducing side effects.
The composition achieves better efficacy at lower concentrations with improved stability, reduced side effects, and effective intraocular pressure reduction, while minimizing visual interference and manufacturing complexity.
Smart Images

Figure 2026182818000001_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present invention belongs to the field of pharmaceuticals, and particularly relates to an ophthalmic pharmaceutical composition for use in the prevention, treatment, or alleviation of ocular diseases in an individual, and use thereof. BACKGROUND ART
[0002] Glaucoma is a disease in which the optic nerve is damaged by high intraocular pressure. In addition to glaucoma, high intraocular pressure may also cause other related diseases such as dry eye, pink eye, or non-arteritic anterior ischemic optic neuropathy (NAION). Intraocular pressure mainly depends on the balance between the secretion rate and the discharge rate of aqueous humor in the eye, and is also affected by the thickness and hardness of the cornea. The normal intraocular pressure is 10 to 22 mmHg, generally about 15 to 16 mmHg, with a maximum fluctuation range of up to 6 mmHg. In addition, intraocular pressure may also vary due to physiological factors such as exercise, heart rate, respiration, and fluid intake, or specific systemic or local drugs.
[0003] So far, a plurality of types of prostaglandin analogs, such as latanoprost, bimatoprost, tafluprost, travoprost, and unoprostone, have been found to effectively reduce intraocular pressure as topical agents. Latanoprost, travoprost and tafluprost are all potent and highly selective PGF2α receptor agonists. Their effect is to reduce intraocular pressure by significantly increasing the aqueous humor outflow through the uveoscleral pathway, and they may also increase the aqueous humor discharge through the trabecular meshwork pathway to a certain extent.
[0004] Currently, various ophthalmic drug formulations containing prostaglandin analogs are being developed and marketed, and among them, many common ophthalmic drug formulations and eye drop solutions all contain preservatives. Preservative-containing eye drop solutions have many drawbacks, and can cause irritant or hypersensitivity reactions, especially when used over long periods, such as in the treatment of glaucoma. The most common preservative in the above formulations is benzalkonium chloride, a quaternary ammonium compound that is always associated with irritant toxic reactions. Single-dose packaging without preservatives can avoid this problem, but it is expensive, requiring not only the use of separate containers for each dose but also the refilling of the drug solution, resulting in a large amount of drug solution remaining in the container and being wasted. Even if the drug solution is administered into the eye, only a small portion is effective due to the limited capacity of the lacrimal sac, and some of the drug solution is released by blinking, while the other is absorbed into the nasolacrimal duct, which can induce harmful drug reactions.
[0005] For active ingredients with low water solubility in drug formulations, oily ophthalmic preparations are generally used. Such preparations can dissolve low-water-soluble drugs more effectively, and therefore usually do not require the addition of pH adjusters or osmotic pressure adjusters. For example, low-water-soluble drugs like cyclosporine are formulated as oil-in-water emulsions, where the active ingredient has some solubility in the oil phase. However, since the oil phase is simply continuously dispersed in the aqueous phase, there is a drawback in that the amount of drug that can be carried is limited. At the same time, oily preparations can adversely affect vision. Whether used as a single oily solution or as an oil-in-water emulsion, they exhibit a refractive index significantly different from that of physiological tears, which can cause visual interference and blurring. Furthermore, compared to single-phase systems (e.g., aqueous or oily solvents), oil-in-water emulsions are more complex to manufacture, especially in sterile conditions, and are more difficult to prepare. Moreover, emulsions usually cannot withstand high-temperature sterilization because their physical properties may be adversely affected. On the other hand, aseptic processing is extremely complex, costly, and carries a high risk of contamination. [Overview of the Initiative]
[0006] Based on the above, many problems still exist with existing ophthalmic formulations, and it is hoped that these will be resolved as soon as possible. In view of this, the present inventor proposes a solution that provides an ophthalmic pharmaceutical composition and its uses that not only has excellent stability but also improves upon conventional side effects and can achieve better efficacy at lower concentrations, and that does not contain water or preservatives.
[0007] According to one embodiment of the present invention, an ophthalmic pharmaceutical composition is characterized by comprising 0.006% w / v to 0.040% w / v of latanoprostene bunod (LBN) or a pharmaceutically acceptable salt thereof, and at least one excipient comprising an oil phase and a liquid carrier of semifluorinated alkanes (SFAs), wherein the composition is microbiologically safe, contains neither water nor preservatives, is formulated as a solution, emulsion or suspension, and the excipient has an oil phase concentration of 10% w / v to 50% w / v, and the solubility of latanoprostene bunod in the excipient is 0.56 mg / mL to 1.21 mg / mL.
[0008] According to one embodiment of the present invention, the excipient has an oil phase concentration of 15% w / v, and the solubility of latanoprostenbunode in the excipient is 0.56 mg / mL.
[0009] According to one embodiment of the present invention, the oil phase is selected from triglyceride oil, mineral oil, medium-chain triglycerides (MCT), oily fatty acids, isopropyl myristate, oily aliphatic alcohols, sorbitan esters, oily sucrose esters, or other oily substances physiologically acceptable to the eye.
[0010] According to one embodiment of the present invention, the excipient has an oil phase concentration of 15% w / v to 30% w / v.
[0011] According to one embodiment of the present invention, the semi-fluorinated alkanes have a refractive index range of 1.29 to 1.35 at 20°C.
[0012] According to one embodiment of the present invention, the semi-fluorinated alkanes are linear or branched alkanes in which a non-fluorinated hydrocarbon segment is bonded to a fully fluorinated hydrocarbon segment.
[0013] According to one embodiment of the present invention, the general formula of the semi-fluorinated alkanes is RFRH, where RF represents the fully fluorinated hydrocarbon segment and RH represents the unfluorinated hydrocarbon segment, and both RF and RH have a linear structure and each has 3 to 20 carbon atoms.
[0014] According to one embodiment of the present invention, the total fluorinated hydrocarbon segment contains 4 to 12 carbon atoms, and the non-fluorinated hydrocarbon segment contains 4 to 10 carbon atoms.
[0015] According to one embodiment of the present invention, the semi-fluorinated alkanes are selected from the group consisting of F4H4, F4H5, F4H6, F4H7, F4H8, F6H2, F6H4, F6H6, F6H7, F6H8 (Perfluorohexyloctane), F6H9, and F6H10.
[0016] According to one embodiment of the present invention, the excipient further comprises a co-solvent and / or a solvent.
[0017] According to one embodiment of the present invention, the cosolvent is an organic solvent selected from glycerin, propylene glycol, polyethylene glycol, and ethanol.
[0018] On the other hand, the present invention provides the above-mentioned ophthalmic pharmaceutical composition for use in the prevention, treatment, or alleviation of eye diseases, including symptoms associated with elevated intraocular pressure, glaucoma, dry eye, pink eye (eye redness), or non-arteritic anterior ischemic optic neuropathy (NAION).
[0019] According to one embodiment of the present invention, the prevention, treatment, or alleviation of glaucoma is achieved by lowering the patient's intraocular pressure.
[0020] According to one embodiment of the present invention, the symptoms of dry eye include "a feeling of dryness in the eyes," "sensitivity to light," "redness of the eyes," "pain in the eyes," "a feeling of a foreign body," "viscous discharge from the eyes," "blurred vision," and / or "decreased vision."
[0021] According to one embodiment of the present invention, the use is for the prevention, treatment, or relief of non-arteritic anterior ischemic optic neuropathy (NAION), and includes administering the ophthalmic pharmaceutical composition to an individual by contact with the eye or by injection into the eye, wherein, when administered to the individual by contact with the eye, the ophthalmic pharmaceutical composition has a latanoprostenbunode concentration of 0.006% w / v to 0.040% w / v and is administered three times a day for three weeks, and when administered to the individual by injection into the eye, the ophthalmic pharmaceutical composition has a latanoprostenbunode concentration of 0.04% w / v and is administered as a single injection.
[0022] As described above, the present invention provides an ophthalmic pharmaceutical composition that does not contain water or preservatives, has excellent stability, improves upon conventional side effects, and can achieve better effects at lower concentrations. [Brief explanation of the drawing]
[0023] [Figure 1] This is a comparative diagram of the intraocular pressure-lowering effect between an ophthalmic pharmaceutical composition (CA202L) according to one embodiment of the present invention and a commercially available drug. [Figure 2] This is a comparative diagram of intraocular pressure changes between an ophthalmic pharmaceutical composition (CA202L) according to one embodiment of the present invention and a commercially available drug. [Figure 3] This is the OSDI (Oral Stress Diagnosis and Response) scale for assessing subjective symptoms of dry eye. [Figure 4] This is comparative data of the degree of eye redness between an ophthalmic pharmaceutical composition (CA202L) according to one embodiment of the present invention and a commercially available drug. DETAILED DESCRIPTION OF THE EMBODIMENTS
[0024] The present invention provides an ophthalmic pharmaceutical composition comprising a therapeutically effective amount of a prostaglandin analog, and at least one excipient comprising an oil phase and a liquid carrier of perfluoroalkanes. The ophthalmic pharmaceutical composition has microbiological stability, is essentially free of water, and contains no preservatives. In addition, according to at least one embodiment of the present invention, the ophthalmic pharmaceutical composition is prepared as a solution, emulsion or suspension.
[0025] The concentration unit "%w / v" as used herein refers to the number of grams (g) of solute contained in 100 milliliters (mL) of the solution. For example, the ophthalmic pharmaceutical composition of the present invention may contain 0.040% w / v of latanoprostene bunod (LBN), which means that 0.040 grams (g) of latanoprostene bunod is contained in 100 milliliters (mL) of the ophthalmic pharmaceutical composition. In addition, in the excipient contained in the ophthalmic pharmaceutical composition of the present invention, the concentration of the oil phase may be 30% w / v, which means that 30 grams (g) of the oil phase is contained in 100 milliliters (mL) of the excipient.
[0026] Specifically, when preparing an ophthalmic pharmaceutical composition containing 0.040% w / v of latanoprostene bunod (LBN), first 0.040 grams (g) of latanoprostene bunod is weighed, and then the total volume is adjusted to 100 milliliters (mL) while adding the excipient in divided portions. In addition, when preparing an excipient with an oil phase concentration of 30% w / v, first 30 grams (g) of the oil phase (for example, medium-chain triglycerides (MCTs)) is weighed, and then the total volume is adjusted to 100 milliliters (mL) while adding the perfluoroalkanes (for example, F6H8) in divided portions.
[0027] Specifically, the prostaglandin analog is an active ingredient that is poorly soluble in water. For example, the prostaglandin analog includes latanoprost, bimatoprost, tafluprost, travoprost, or unoprostone, and is preferably latanoprostene bunod (LBN) or a pharmaceutically acceptable salt thereof.
[0028] More specifically, the concentration of the prostaglandin analog is 0.005% w / v to 0.100% w / v, for example, 0.005% w / v, 0.006% w / v, 0.010% w / v, 0.012% w / v, 0.015% w / v, 0.020% w / v, 0.024% w / v, 0.025% w / v, 0.030% w / v, 0.035% w / v, 0.040% w / v, 0.045% w / v, 0 The w / v values are 0.050% w / v, 0.055% w / v, 0.060% w / v, 0.065% w / v, 0.070% w / v, 0.075% w / v, 0.080% w / v, 0.085% w / v, 0.090% w / v, 0.095% w / v, or 0.100% w / v, preferably 0.006% w / v to 0.040% w / v, and more preferably 0.012% w / v to 0.024% w / v.
[0029] Specifically, the excipient has an oil phase concentration of 10% w / v to 50% w / v, for example, 10% w / v, 15% w / v, 20% w / v, 25% w / v, 30% w / v, 35% w / v, 40% w / v, 45% w / v, or 50% w / v, preferably 15% w / v to 30% w / v, more preferably 15% w / v to 20% w / v, and particularly preferably 15% w / v.
[0030] Specifically, the solubility of the prostaglandin analog in the excipient is 0.19 mg / mL to 1.21 mg / mL, for example, 0.19 mg / mL, 0.25 mg / mL, 0.30 mg / mL, 0.35 mg / mL, 0.40 mg / mL, 0.45 mg / mL, 0.50 mg / mL, 0.56 mg / mL, 0.60 mg / mL, 0.65 mg / mL, 0.70 mg / mL, 0.75 mg / mL, 0.80 mg / mL, 0.85 mg / mL, 0.90 mg / mL, 0.95 mg / mL, 1.00 mg / mL, 1.05 mg / mL, 1.10 mg / mL, 1.15 mg / mL, 1.20 mg / mL, or 1.21 mg / mL, preferably 0.56 mg / mL to 1.21 mg / mL, and more preferably 0.56 mg / mL.
[0031] Specifically, the hemifluorinated alkanes described herein are linear or branched alkanes in which some of the hydrogen atoms are substituted with fluorine. In at least one embodiment, the hemifluorinated alkanes comprise at least one nonfluorinated hydrocarbon segment and at least one fully fluorinated hydrocarbon segment, preferably a linear or branched alkane of one nonfluorinated hydrocarbon segment bonded to one fully fluorinated segment. More specifically, the hemifluorinated alkanes are (F(CF2)n(CH2)mH) hemifluorinated alkanes, or (F(CF2)n(CH2)m(CF2)oF) hemifluorinated alkanes in which one nonfluorinated segment is sandwiched between two fully fluorinated segments.
[0032] According to some embodiments of the present invention, the general formula of the hemifluorinated alkanes is RFRH or RFRHRF, where RF represents the total fluorine segment and RH represents the non-fluorine segment, but may also be written as FnHm and FnHmFo. F represents the total fluorine segment, H represents the non-fluorine segment, and n, m, and o represent the number of carbon atoms in each segment. For example, F3H3 represents perfluoropropylpropane. Unless otherwise specified, F3H3 represents 1-perfluoropropylpropane. Preferably, the hemifluorinated alkanes conform to the above general formula and each segment (n, m, o) independently has 3 to 20 carbon atoms.
[0033] In some preferred embodiments of the present invention, the hemifluorinated alkanes have an RFRH structure, where both RF and RH are linear structures and each contains 3 to 20 carbon atoms. Preferably, RF contains 4 to 12 carbon atoms and RH contains 4 to 8 carbon atoms. According to some preferred embodiments of the present invention, the hemifluorinated alkanes include F4H4, F4H5, F4H6, F4H7, F4H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, and F6H10, and more preferably, the hemifluorinated alkane is F6H8.
[0034] While not limited to any particular theory, the inventors believe that the chemical and physiological properties of semifluorinated alkane substances are suitable for the ophthalmic pharmaceutical composition of the present invention. For example, they are stable, colorless, and have a density of approximately 1.1 to 1.7 g / cm³. 3 Furthermore, the surface tension can reach a minimum of 19 mN / m, and although RFRH-type semifluorinated alkanes are insoluble in water, they possess a certain degree of amphiphilicity, with lipophilicity increasing as the non-fluorinated segment lengthens. In addition, since the refractive index of semifluorinated alkanes is close to that of tears (approximately 1.333), the effect on vision is extremely small and they do not cause blurring of vision.
[0035] Specifically, the oil phase can be selected from the group consisting of triglyceride oil, mineral oil, medium-chain triglycerides (MCTs), oily fatty acids, isopropyl myristate, oily aliphatic alcohols, sorbitan esters, oily sucrose esters, or other oily substances physiologically acceptable to the eye, and is preferably medium-chain triglycerides (MCTs). Although not limited to a specific theory, MCTs contribute to maintaining the lipid layer of the tear film, and therefore, by adding them to ophthalmic pharmaceutical compositions, the stability of the lipid layer can be enhanced. In addition, MCTs are digested and absorbed more rapidly in the human body, and furthermore, because MCTs are liquid at room temperature and have the properties of being nonpolar and highly hydrophobic, they can contribute to the dissolution of oily substances in drug delivery systems. Moreover, because MCTs have low viscosity, they spread easily on surfaces, preventing reflexive release due to blinking of the eyelids, and can form stable emulsions, making them beneficial for pharmaceutical applications, especially in ophthalmic drugs.
[0036] Specifically, the excipient has an oil phase concentration of approximately 50% w / v or less, for example, 10% w / v, 15% w / v, 20% w / v, 25% w / v, 30% w / v, 35% w / v, 40% w / v, 45% w / v, or 50% w / v.
[0037] While not limited to any particular theory, the present invention is particularly suitable for drugs / active ingredients that are poorly soluble in water, which can be quite challenging in the preparation of ophthalmic formulations. As described in this specification, if the solubility of a compound is "slightly soluble," "slightly soluble," "very slightly soluble," or "almost insoluble" (according to the 6th edition of the European Pharmacopoeia), the compound is considered to be poorly soluble in water, specifically, for example, an active ingredient with a solubility in water of less than about 1 mg / mL at a neutral pH of 6.0 to 8.0 and room temperature of 15 to 25°C.
[0038] According to some embodiments of the present invention, additional liquid excipients may be added to improve solubility, ensuring that the active ingredient is completely dissolved. Specifically, the additional liquid excipients are cosolvents and / or solvents. The cosolvents are preferably organic cosolvents, such as oily substances like glyceride oils, liquid waxes, or liquid paraffin, or other highly biocompatible organic solvents. According to some embodiments of the present invention, the cosolvents may be selected from organic solvents such as glycerin, propylene glycol, polyethylene glycol, and ethanol.
[0039] In specific examples, F6H8 and MCTs are used as the semi-fluorinated alkanes and oil phase, respectively, according to the present invention. Table 1 shows a comparison of the physical properties of F6H8, MCTs, and water. Of these physical properties, surface tension, viscosity, and refractive index are important parameters that affect the action of eye drops in the eye.
[0040] [Table 1]
[0041] Since both F6H8 and MCTs used in this invention have refractive indices close to those of water, it is presumed that the composition of this invention can effectively avoid large differences between its components and human tears, and furthermore, avoid blurring of vision. [Examples]
[0042] To evaluate the compatibility between MCTs and F6H8, the present invention prepared excipients at different concentrations, using an oil phase as the solute and a liquid support of semifluorinated alkanes (SFAs) as the solvent. As shown in Table 1, all excipients at all oil phase concentrations were clear.
[0043] [Table 2]
[0044] [Examples]
[0045] In Example 2, 5 mg / mL of LBN was selected as the active ingredient for the initial experiments of the present invention. After 5 mg / mL of LBN was added to pure MCTs, it was heated to 80°C, shaken uniformly to ensure complete dissolution, and then cooled to room temperature. The saturation solubility of LBN in pure MCTs, as measured by HPLC, was approximately 3.4 mg / mL.
[0046] To confirm the stability of LBN in the excipient formed to dissolve MCTs in F6H8, and to mitigate potential eye irritation caused by MCTs in the final product, the concentration of MCTs was reduced in this invention. The target solubility was set at twice the LBN concentration in the commercially available product VYZULTA, which contains 0.24 mg / mL of LBN, so the target was set to exceed 0.48 mg / mL.
[0047] Specifically, the excipient has an oil phase concentration of 10% w / v, 15% w / v, 20% w / v, 25% w / v, 30% w / v, 35% w / v, 40% w / v, 45% w / v, and 50% w / v, preferably 10% w / v, 15% w / v, and 30% w / v, and the solubility of LBN is 0.19 mg / mL, 0.56 mg / mL, and 1.21 mg / mL, respectively (as shown in Table 3). In further examples, the concentration used in the present invention is 15% w / v, and the solubility corresponding to LBN is 0.56 mg / mL.
[0048] [Table 3]
[0049] [Examples]
[0050] After confirming that the saturation solubility of LBN in pure MCTs is approximately 3.4 mg / mL, this example prepared ophthalmic pharmaceutical compositions with excipients such as 1 mg / mL LBN dissolving in pure MCTs, 1 mg / mL LBN dissolving in MCTs at a concentration of 50% w / v, and 1 mg / mL LBN dissolving in MCTs at a concentration of 30% w / v. Initial stability measurements were then performed at different excipient ratios. The effect of the decrease in MCT concentration on stability was examined over long periods (1 week, 2 weeks, 1 month, 3 months, and 6 months) at 25°C and 40°C, and the results are shown in Table 4. Specifically, the effective concentration values (in %w / v) shown in the table represent the stability results, and more specifically, the magnitude of these effective concentration values is positively correlated with stability.
[0051] [Table 4]
[0052] As can be seen from the stability data in Table 4, formulations with excipients that allow 1 mg / mL of LBN to dissolve in pure MCTs and formulations that allow 1 mg / mL of LBN to dissolve in MCTs at a concentration of 30% w / v did not show significant variation in stability data from T0 to 3 months at 25°C and 40°C. However, some data showed variation within a range of ±10%, which may be due to analytical methods, including sample preparation processes, that have not been previously validated. [Examples]
[0053] In Example 4 of the present invention, following the data in Table 4, stability measurements of excipients were performed to determine whether 0.24, 0.12, and 0.06 mg / mL of LBN were soluble in MCTs at a concentration of 30% w / v, with the same time and temperature conditions as described above.
[0054] [Table 5]
[0055] As shown in Table 5, the variation in excipients that allow LBN at concentrations of 0.06 to 0.24 mg / mL to dissolve in 15% w / v MCTs is approximately 20% on average. This indicates that the lower the concentration, the greater the variation over 3 months, suggesting poorer stability. [Examples]
[0056] Referring to Figures 1 to 4, in this example, the intraocular pressure-lowering effect, improvement of dry eye symptoms, and reduction of the degree of eye redness as a side effect were measured for CA202L (experimental number, component is an excipient such that 0.012% w / v or 0.024% w / v LBN is dissolved in 15% w / v MCTs) containing 0.012% w / v and 0.024% w / v LBN, and the commercially available ophthalmic drug VYZULTA (0.024% w / v LBN). Subjects administered one drop of the drug to their eye once every night, and their intraocular pressure (IOP) was measured after 7 and 14 days, respectively. They also completed a self-assessment dry eye symptom questionnaire and evaluated the degree of eye redness. More specifically, the aforementioned self-assessment dry eye symptom questionnaire refers to the OSDI questionnaire (Ocular Surface Disease Index), a self-administered questionnaire tool used to evaluate the impact of ocular surface diseases (especially dry eye) on patients' daily lives. It primarily focuses on the following three aspects: visual function (Function), such as difficulties during activities like reading, driving at night, using a computer, or watching television; ocular symptoms (Symptoms), such as the frequency of unpleasant symptoms like dryness, tingling, foreign body sensation, and fluctuations in visual acuity; and environmental triggers (Environmental triggers), including the degree of eye discomfort caused by wind, air conditioning, or dry environments. The OSDI questionnaire asks respondents to rate the frequency of symptoms or difficulties for each question on a scale from 0 to 4, i.e., 0 = never, 1 = sometimes, 3 = often, 4 = always. The final score is obtained by multiplying the sum of all scores by 25 and dividing by the number of valid responses. A score of 0 to 12 indicates no dry eye, 13 to 22 indicates mild dry eye, 23 to 32 indicates moderate dry eye, and 33 to 100 indicates severe dry eye.
[0057] The study involved a total of 10 subjects. The experimental conditions were as follows: all 10 subjects in the control group received VYZULTA eye drops containing 0.024% w / vLBN in their left eyes; five subjects received CA202L eye drops containing 0.012% w / vLBN in their right eyes; and the remaining five subjects received CA202L eye drops containing 0.024% w / vLBN in their right eyes. See Figures 1, 2, and 3 for the results.
[0058] The results showed that after 14 days of use, 0.012% w / v CA202L and 0.024% w / v VYZULTA showed comparable intraocular pressure lowering effects, but 0.024% w / v CA202L was significantly superior to 0.024% w / v VYZULTA. Thus, the ophthalmic pharmaceutical composition of the present invention exhibits effects similar to commercially available drugs even when the content of the active ingredient is lower than that of commercially available drugs, and furthermore, when the content of the active ingredient is the same in both, the composition of the present invention shows a superior effect in improving high intraocular pressure (Figures 1 and 2).
[0059] In addition, in the evaluation of side effects such as dry eye symptoms and conjunctival hyperemia, according to the subjects' self-assessments, the dry eye score and degree of conjunctival hyperemia were both lower when using CA202L than when using VYZULTA. Therefore, the CA202L formulation of the present invention has fewer side effects than VYZULTA (Figure 3).
[0060] On the other hand, the present invention provides applications for ophthalmic pharmaceutical compositions used for the prevention, treatment, or alleviation of eye diseases in individuals, wherein said eye diseases include symptoms associated with increased intraocular pressure, glaucoma, dry eye, pink eye (eye redness), or non-arteritic anterior ischemic optic neuropathy (NAION).
[0061] As mentioned above, prevention and treatment effects can be achieved by lowering intraocular pressure, which is one of the causes of these eye diseases. Dry eye symptoms include "dryness of the eyes," "sensitivity to light," "redness of the eyes," "pain in the eyes," "foreign body sensation," "viscous discharge," "blurred vision," and / or "decreased vision."
[0062] Furthermore, a method for treating or alleviating retinal ganglion cell (RGC) damage caused by non-arteritic anterior ischemic optic neuropathy (NAION) is to administer the ophthalmic pharmaceutical composition to the individual by bringing it into contact with the eye or by injecting it into the eye.
[0063] Furthermore, the prevention, treatment, or relief of non-arteritic anterior ischemic optic neuropathy (NAION) includes administering the ophthalmic pharmaceutical composition to an individual by bringing it into contact with the eye or by injecting it into the eye, and such individual is, for example, a rat, mouse, or human animal.
[0064] When the ophthalmic pharmaceutical composition is administered to an individual by contact with the eye, its concentration is 0.006% w / v to 0.040% w / v, and it is administered three times a day for three weeks. Specifically, the concentrations are 0.006% w / v, 0.010% w / v, 0.015% w / v, 0.020% w / v, 0.025% w / v, 0.030% w / v, 0.035% w / v, or 0.040% w / v.
[0065] When the ophthalmic pharmaceutical composition is administered to an individual by injection into the eye, its concentration is 0.04% w / v, and it is administered by a single injection. [Examples]
[0066] In this embodiment, the present invention measures the effect of CA202L (experimental number, component is an excipient such that 0.006% w / v or 0.040% w / v LBN dissolves in 15% w / v MCTs) containing 0.006% w / v and 0.040% w / v LBN using a mouse model (NAION C57BL / 6). For the results, please refer to Figure 4.
[0067] For the construction of the NAION C57BL / 6 mouse model, a photochemical thrombosois method was used, in which 1.25 mL of Rose Bengal was injected into the tail vein of the mouse, followed by NAION induction using an NY-YAG green laser (spot diameter 300 μm, power 50 mW, duration 1 second, 15 spots).
[0068] The experimental procedure involved inducing mice to receive, then administering placebo, 0.006% w / v CA202L eye drops three times daily for three weeks, 0.040% w / v CA202L eye drops three times daily for three weeks, and a single intraocular injection of 0.040% w / v CA202L. Immunostaining was performed, followed by counting of Brn3A (biomarker) + retinal ganglion cells (RGCs) (unit: cells / mm²). 2 ) was held.
[0069] As shown in Figure 4, the vertical axis represents the Brn3A+RGC count results, and the horizontal axis represents, in order, the control group, placebo group, 0.040% w / v eye drop group, 0.006% w / v eye drop group, and 0.04% w / v intraocular injection group. As can be seen from the results, after the placebo group mice were induced, the count results decreased from 2437 in the control group to 1546, and the RGC cell count decreased by approximately 36%. When CA202L eye drops at 0.006% w / v or 0.040% w / v were used after induction, or when 0.04% w / v CA202L was injected intraocularly as a single dose, a 27–36% RGC protective effect was obtained, demonstrating that CA202L has a significant effect in mitigating RGC damage caused by NAION (cell counts decreased by only about 23–26%, and RGC counts were 1814–1830). [Explanation of Symbols]
[0070] none
Claims
1. Latanoprostene bunod (LBN) in an amount of 0.006% w / v to 0.121% w / v or a pharmaceutically acceptable salt thereof, An excipient comprising an oil phase and a liquid carrier of semifluorinated alkanes (SFAs), Includes, The aforementioned composition is microbiologically safe and contains neither water nor preservatives. The aforementioned composition is formulated as a solution, emulsion, or suspension. The excipient has an oil phase concentration of 10% w / v to 50% w / v. The oil phase is a medium-chain triglyceride (MCT). An ophthalmic pharmaceutical composition characterized by the following features.
2. A pharmaceutically acceptable salt thereof comprising 0.006% w / v to 0.1% w / v latanoprostene bunod (LBN) or a pharmaceutically acceptable salt thereof, The ophthalmic pharmaceutical composition according to feature 1.
3. The excipient has an oil phase concentration of 15% w / v, and the solubility of latanoprostenbunode in the excipient is 0.56 mg / mL. The ophthalmic pharmaceutical composition according to feature 1.
4. The excipient has an oil phase concentration of 15% w / v to 30% w / v. The ophthalmic pharmaceutical composition according to feature 1.
5. The aforementioned semi-fluorinated alkanes have a refractive index range of 1.29 to 1.35 at 20°C. The ophthalmic pharmaceutical composition according to feature 1.
6. The aforementioned semi-fluorinated alkanes are linear or branched alkanes in which a non-fluorinated hydrocarbon segment is bonded to a fully fluorinated hydrocarbon segment. The ophthalmic pharmaceutical composition according to feature 1.
7. The general formula for the aforementioned semi-fluorinated alkanes is RFRH, where RF represents the total fluorinated hydrocarbon segment and RH represents the non-fluorinated hydrocarbon segment, and both RF and RH have a linear structure and each has 3 to 20 carbon atoms. The ophthalmic pharmaceutical composition according to feature 6.
8. The total fluorinated hydrocarbon segment contains 4 to 12 carbon atoms, and the non-fluorinated hydrocarbon segment contains 4 to 10 carbon atoms. The ophthalmic pharmaceutical composition according to feature 7.
9. The aforementioned semi-fluorinated alkanes are selected from the group consisting of F4H4, F4H5, F4H6, F4H7, F4H8, F6H2, F6H4, F6H6, F6H7, F6H8 (Perfluorohexyloctane), F6H9, and F6H10. The ophthalmic pharmaceutical composition according to feature 1.
10. The excipient further comprises a co-solvent and / or a solvent. The ophthalmic pharmaceutical composition according to feature 1.
11. The co-solvent is an organic solvent selected from glycerin, propylene glycol, polyethylene glycol, and ethanol. The ophthalmic pharmaceutical composition according to feature 9.
12. It is used to prevent, treat, or alleviate eye diseases, including symptoms associated with elevated intraocular pressure, glaucoma, or non-arteritic anterior ischemic optic neuropathy (NAION). Uses of the ophthalmic pharmaceutical composition according to any one of claims 1 to 11.
13. The prevention, treatment, or alleviation of the aforementioned glaucoma involves lowering the patient's intraocular pressure. The use described in feature 12.
14. Symptoms associated with elevated intraocular pressure include dry eyes and pink eye (eye redness), which are side effects. The use described in feature 12.
15. The aforementioned symptoms of dry eye include "a feeling of dryness in the eyes," "sensitivity to light," "redness of the eyes," "pain in the eyes," "a feeling of a foreign body," "viscous discharge from the eyes," "blurred vision," and / or "decreased vision." The use described in feature 14.
16. Uses for the prevention, treatment, or relief of the aforementioned non-arteritic anterior ischemic optic neuropathy (NAION), The ophthalmic pharmaceutical composition according to any one of claims 1 to 11 is administered to an individual by contact with the eye or by injection into the eye, When administered to the individual by contact with the eye, the ophthalmic pharmaceutical composition has a latanoprostenbunode concentration of 0.006% w / v to 0.040% w / v, and is administered three times a day for three weeks. When administered to the individual by injection into the eye, the ophthalmic pharmaceutical composition has a concentration of latanoprostenbunode of 0.04% w / v and is administered as a single injection. The use described in feature 12.
